PREBOOK THIS REPORT - SAVE 10%

Virtual Clinical Trials Market - Global Outlook & Forecast 2022-2027

TO BE PUBLISHED : Oct 2022 | Pages : 270

THE GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE WAS VALUED AT USD 1.93 BILLION IN 2021 AND IS EXPECTED TO REACH USD 5.10 BILLION BY 2027, GROWING AT A CAGR OF 17.59% DURING THE FORECAST PERIOD.

The Global Virtual Clinical Trials Market Size, Share, Growth Forecast by: 

  • Study Type: Interventional and Others
  • Phases: Late Stage and Early Stage
  • Therapeutic Area: Oncology, Rare & Genetic Diseases, CNS, Immunology, and Other
  • Company Size: Small & Mid-Sized and Large Sized
  • Geography: North America, Europe, APAC, Latin America, and Middle East & Africa

Industry Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share, & Forecast 2022-2027

Prebook Tag
Licence Types What are these?
10 % OFF

Save 10% on this report.
Discount already applied

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

270 Pages

icon-table

37 Tables

icon-chart

152 Charts

icon-region

5 Regions

icon-country

18 Countries

icon-company

24 Companies

icon-market

5 Market Segment

VIRTUAL CLINICAL TRIALS MARKET REPORT SCOPE

Report Attribute Details
Market Size (2027) USD 5.10 Billion
Market Size (2021) USD 1.93 Billion
CAGR (2022-2027) 17.59%
Base Year 2021
Forecast Year 2022-2027
Market Segments Study Type, Phases, Therapeutic Area, Company Size, and Geography
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
KEY VENDORS Dassault Systèmes, Medable, Science 37, and THREAD

The global virtual clinical trials market is expected to reach USD 5.10 billion by 2027 from USD 1.93 billion in 2021, growing with a CAGR of 17.59% from 2022-2027. The virtual clinical trials market is one of the innovative approaches for traditional clinical trials, through remote monitoring and more patient-centric approaches. These virtual clinical trials adoption was high during the COVID-19 pandemic period and the usage of decentralized clinical trials components application rate. Most clinical trial conductors started to move towards the decentralized or hybrid clinical trial model.

Virtual clinical trials are also known as de-centralized clinical trials. Although the vendors adopted virtual clinical trials for many years, however, it was very slow adoption before the pandemic. The virtual clinical trials market includes the application of digital tools and technological processes that take trials from healthcare settings to patients’ homes or places of work. The reduction in site visits, associated time, and economic cost cuttings eliminate the burden placed on patients and solve the challenges for trial participation. The virtual clinical trials market brought significant advantages and reduced major challenges like patient retention, recruitment, and more. These are the factors that fuel market growth.

MARKET TRENDS

Virtual clinical trials are an alternative method to traditional clinical trial methods. The new connected devices power clinical trial activities with better clinical data collection, analysis, and interpretations play a significant role. Clinical trial monitoring devices, clinical trial software, eCOA & ePRO, and eConsent are some digital tools that strengthen clinical trial activities and give a new shift in the clinical trial industry. On another side, the bring-your-own-devices strategy, a newly adopted trend, is widely accepted among CROs and sponsors. This new strategy allows the trial participants to deliver required data with their own internet-enabled solutions. Technological advances and confidence in improved study outcomes can bring new solutions.

The latest retrospective approach, adopting the synthetic clinical trial approach, delivers significant clinical development. Many biopharma and medical device companies face challenges in finding participants for clinical trials; this synthetic arm process is one of the easy methods, using the innovative approach for collecting and comparing data called the synthetic control arm. This is one of the fully new approaches in the virtual clinical trials market and is expected to drive significant growth. In addition, the involvement of Artificial Intelligence (AI) in clinical trials significantly changes the trial procedure as AI can expedite target validation, clinical trial design, and patient identification for participation in virtual clinical trials.

INDUSTRY DRIVERS

The COVID-19 pandemic is the significant factor that shifted the traditional clinical trials approach to the virtual clinical trials market. The rapid surge of COVID-19 infections poses substantial challenges in the clinical trial space, where the virtual clinical trial model significantly pushed the biopharmaceutical and medical device industry towards decentralization (DCT). During the COVID-19 pandemic period, approximately 87% of clinical trial sponsors and contract research organizations decentralized the clinical trial activities compared with 28% only pre-covid period.

The market players and the companies pioneer in clinical trials activities understand that decentralization in clinical trials is the future of the clinical trials space. Over the last few years, decentralization has rapidly grown in the clinical trials industry. Decentralization of clinical trials has significant potential since the virtual clinical trials are independent of regional/geographical locations and are implemented through digital health platforms as well as mobile and local healthcare segments; this makes the providers eliminate the constraints associated with the traditional model.

Regulatory changes in favor of DCT: The pandemic period (COVID-19 Crisis) has supercharged the changes for virtual clinical trials from regulatory agencies worldwide. Including Food Drugs Administration (FDA), UK’s Medicine and Healthcare Product Regulatory Agency (MHRA), European Medicine Agency (EMA), China’s Center for Drug Evaluation (CDE), and Singapore Health Science Authority (HSA) have made revolutionary regulations towards the virtual clinical trials market.

On another side, the challenges associated with the virtual clinical trials model, such as the high expenditure required for the initial implementation, data reliability and integrity, and varied state law and regulations, are some factors that hamper the market growth. In addition, the increasing digital tools and growing risk of cyber-attacks are challenging aspects of the virtual clinical trials market growth.

SEGMENTATION ANALYSIS

INSIGHTS BY STUDY TYPE
The global virtual clinical trials market by study type is segmented into interventional and others. The interventional study type segment accounts for an 80.15% higher market share and dominates other segments. The increasing R&D activities in the medical industry led to increased clinical trials. In interventional study type, the growing application of a digital tool for clinical trial data collection and analysis gives high demand for virtual clinical trials platform that increases the segmental growth. Also, with the increasing infection rate of SARS-COV-2, a higher number of clinical trials for vaccine development registered in the period 2020 to 2022, which has increased the adoption of virtual tools in clinical trials.

INSIGHTS BY STAGE OF DEVELOPMENT
The early and late phases are two primary segments under the stage of development in the global virtual clinical trials market. The early phase segment accounted for 41.55% market share, and the late phase segment accounted for 58.45% market share in 2021. The high number of clinical trials are currently accounted for the phase III & phase IV, which is increasing the adoption of DCT platforms for data accuracy and better outcomes. As well as increasing adoption of DCT platforms and tools in phase, I & phase II trial procedures for patient participation will drive the market growth of the early phase segment in 2021.

INSIGHTS BY THERAPY AREA
The global virtual clinical trials market is segmented into cancer, CVD, infectious diseases, gastroenterology disorders, musculoskeletal diseases, nervous system, and other indications by therapy area. The oncology segment accounted for 44.85% higher market share in the virtual clinical trials market in 2021 and dominated all other segments. The de-centralized clinical trials are majorly accounted for oncology therapeutic areas. More home-based clinical trials are adopted in the diseases segment. This is more patient-centric and helps them provide better clinical outcomes to the clinical trial sponsors. Most of the major market players also show the major de-centralized clinical trials are associated with cancer indications. In 2020, the oncology therapeutic area showed more than 22% for adopting de-centralized clinical trials.

The rare and genetic diseases segment is second, accounting for 15.54% of the market share. Increasing prevalence and constantly addressing rare new diseases and genetic diseases drive the high demand for clinical research. Rare and genetic disorders are one of the major challenging segments in traditional clinical trials segment. This is easily overcome using virtual clinical trials, especially in patient recruitment, retention, and more. Globally more than 6,000 rare diseases the time addressed. It might be increasing in the upcoming time, which will drive the demand for clinical research activities; the increasing prevalence of genetic diseases and rare diseases are the factors that drive the demand for de-centralized clinical trial adoption.

GEOGRAPHICAL LANDSCAPE

North America is the leading region in the global virtual clinical trials market, accounting for 53.54% market share. The increasing clinical trial activities, well-established and advanced clinical trial infrastructure, and adoption of decentralization in clinical trials over the last decades have driven the high market growth in the North American region. Behind North America, Europe is one of the leading regions for virtual clinical trials. The increased acceptance of digital and more connected technologies, the high patient population, and increasing awareness among clinical trial investigators, sponsors, and contract research organizations about virtual clinical trials drive the market growth in the region. In addition, larger geographical landmass and limited healthcare settings make virtual clinical trials an ideal solution for Europe.

APAC is still in the infant stage of adopting virtual clinical trials, but it has vast opportunities to deliver to the virtual clinical trials market. In recent years, clinical trial activities in APAC countries significantly increased. Currently, APAC is well known for its clinical trial industry hub. Large patient populations, diverse ethnicities & geographies, treatment demanding populations, similar diseases pattern, increasing technology adoption in clinical trials, and rapidly growing biopharma industries are some key elements that accelerate virtual clinical trials market growth.

VENDOR LANDSCAPE

Medable, Science 37, THREAD, Dassault Systèmes (Medidata), IQVIA, Clinical ink, Castor, ObvioHealth, Labcorp Drug Development, ERT, Signant Health, Covance, Jeeva, Accenture, and Delve Health are some of the significant players in the global virtual clinical trials market. Further, factors such as increasing drug development focused by various big pharma and biotech companies, continuously increasing their expenditure on research and development activities, clinical trials, and development of advanced solutions triggered high competency in the biopharmaceutical industry. Increasing competition in the pharma industry directly impacts the competitiveness in the virtual clinical trial market.

THREAD offers a unique, innovative, and highly advanced decentralized clinical trial platform in the virtual clinical trials market. THREAD is a fully configurable and singular DCT platform with services that deliver global scalability and rapid flexibility from DCT study design. In 2022, the company acquired inVibe to ingrate the voice of the trial participants and broaden the trial design and research capabilities.

Frequently Asked Questions

What is the size of the global virtual clinical trials market?

The global virtual clinical trials market size was valued at USD 1.9 billion in 2021 and is expected to reach USD 5.10 billion by 2027.

What is the global virtual clinical trials market growth?

The global virtual clinical trials market share is expected to grow at a CAGR of 17.59% from 2022 to 2027.

What are the trends in the global virtual clinical trials market?

The adoption of the “bring your own device strategy” in virtual clinical trials, new connected devices powers clinical trials with better data, and the adoption of synthetic clinical trials are significant trends in the global virtual clinical trials market.

Who are the key players in the global virtual clinical trials market?

Dassault Systèmes, Medable, Science 37, and THREAD are the key vendors in the global virtual clinical trials market.

Which region will dominate the global virtual clinical trials market share?

North America is the leading region in the global virtual clinical trials market. Higher clinical trial activities are performed in North America with higher adoption of advanced tools like the eClinical tools in clinical trial activities. It is one of the highly developed regions in clinical trials as well as technology adoption.

Download Free Sample

The global virtual clinical trials market is expected to grow at a CAGR of approximately 17.59% from 2022 to 2027.

The following factors are likely to contribute to the growth of the global virtual clinical trials market during the forecast period:

  • Covid-19 Accelerate the Virtual Clinical Trials Adoption
  • Decentralization of Clinical Trials is a Future of Clinical Trials
  • Regulatory Changes in Favour of Virtual Clinical Trials

Base Year: 2021

Forecast Year: 2022-2027

The report considers the present scenario of the global virtual clinical trials market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.

Key Vendors

Key Company Profiles

  • Dassault Systèmes
    • Business Overview
    • Product Offerings
    • Key Strategies
    • Key Strengths
    • Key Opportunities
  • Medable
  • Science 37
  • THREAD

Key Companies To Watch

  • Accenture
    • Business Overview
    • Product Offerings
    • Key Strategies
    • Key Strengths
    • Key Opportunities
  • Castor
  • Clinical ink
  • Clario
  • Delve Health
  • eClinicalHealth
  • IQVIA
  • Labcorp Drug Development
  • ObvioHealth
  • Signant Health
  • Thermo Fisher Scientific

Other Prominent Vendors

  • Advarra
    • Business Overview
    • Product Offerings
  • Curavit Clinical Research
  • CMIC Holdings
  • Icon Plc
  • Jeeva Informatics Solutions
  • LEO Innovation Lab
  • Oracle
  • Paraxel International Corporation
  • ProPharma Group

Segmentation by Study Type

  • Interventional
  • Others

Segmentation by Phases

  • Late Stage
  • Early Stage

Segmentation by Therapeutic Area

  • Oncology
  • Rare & Genetic Diseases
  • CNS
  • Immunology
  • Other

Segmentation by Company Size

  • Small & Mid-Sized
  • Large Sized

Segmentation by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa

For more details, please reach us at enquiry@arizton.com

For more details, please reach us at enquiry@arizton.com

Select a license type that suits your business needs

single-user Single User Licence
$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Prebook Tag
Licence Types What are these?
10 % OFF

Save 10% on this report.
Discount already applied

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date